Core Viewpoint - Akari Therapeutics Plc has successfully priced a private placement financing round expected to raise approximately 0.87 per ADS, with additional payments for warrants [2][4] - Gross cash proceeds from the offering are expected to be around $6.6 million before deducting fees and expenses [3] - The private placement is anticipated to close on or about March 5, 2025, subject to customary closing obligations [5] Company Overview - Akari Therapeutics is focused on developing next-generation precision bi-functional antibody drug conjugates (ADCs) for cancer treatment [8] - The lead candidate, AKTX-101, targets the TROP2 receptor and utilizes a novel PH1 payload designed to disrupt RNA splicing in cancer cells, potentially overcoming limitations of current ADCs [8][9] - Preclinical studies indicate that AKTX-101 has superior activity, prolonged survival, and better tolerability compared to existing ADCs [8][9]
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules